During 2018 Q2 the big money sentiment decreased to 1.09. That’s change of 0.26, from 2018Q1’s 1.35. 10 investors sold all, 25 reduced holdings as Theravance Biopharma, Inc. ratio fall. 26 rose positions while 12 funds acquired positions. Funds hold 35.37 million shares thus 0.68% less from 2018Q1’s 35.61 million shares.
Natl Bank Of America De accumulated 0% or 36,932 shs. Fmr Ltd Liability Corp owns 0.02% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 8.08M shs. Barclays Public Ltd invested 0% of its capital in Theravance Biopharma, Inc. (NASDAQ:TBPH). Germany-based Dekabank Deutsche Girozentrale has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Swiss Bancshares holds 75,142 shs or 0% of its capital. State Board Of Administration Of Florida Retirement Systems, Florida-based fund reported 28,578 shs. State Of Wisconsin Invest Board holds 43,600 shs. Pictet Asset Management Limited stated it has 0% of its capital in Theravance Biopharma, Inc. (NASDAQ:TBPH). Legal And General Gp Public Ltd Com stated it has 13,742 shs. State Of New Jersey Common Pension Fund D reported 0.02% stake. Peak6 Invs Lp owns 913 shs or 0% of their US capital. State Common Retirement Fund invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Voya Invest Mngmt Limited Liability Company has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 17,575 shs. Senzar Asset Ltd Liability Co reported 1.79% of its capital in Theravance Biopharma, Inc. (NASDAQ:TBPH). Blackrock holds 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH) or 3.75M shs.
Theravance Biopharma, Inc. had 5 sales and 1 buying transaction since May 18, 2018. This’s net activity of $2.11 million. MALKIEL BURTON G had bought 1,000 shs worth $22,540. On Tuesday, August 14 GALA RENEE D also sold $1.17M worth of Theravance Biopharma, Inc. (NASDAQ:TBPH). On Wednesday, September 12 $182,201 worth of Theravance Biopharma, Inc. (NASDAQ:TBPH) was sold by WORBOYS PHILIP D.
Theravance Biopharma Inc – Ordinary Shares (NASDAQ:TBPH) had an increase of its shares shorted by 0.44%. FINRA announced in November TBPH’s total 6.02M shares shorted. Previously was reported up change of 0.44% from 6.00M shares. Previous TBPH’s position will need 44 days to recover. It has 138,600 average volume. Theravance Biopharma Inc – Ordinary Shares float short is 18.07%.
Ticker’s shares touched $25.81 during the last trading session after 5.13% change.Theravance Biopharma, Inc. is downtrending after having declined 11.71% since November 10, 2017. TBPH has 463,648 volume or 96.60% up from normal. The stock underperformed the S&P 500 by 27.33%.
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics.The company has $1.42 billion market cap. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.Currently it has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.
A couple more Theravance Biopharma, Inc. (NASDAQ:TBPH) news were brought out by: Benzinga.com which released on November 04, 2018 “The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs”, also Benzinga.com on November 06, 2018 brought out “The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos …”, the next Streetinsider.com is “Theravance Biopharma (TBPH) to Sell VIBATIV to Cumberland Pharmaceuticals (CPIX)” on November 06, 2018. Seekingalpha.com has article titled “Key events next week – healthcare”.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.